Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Equity (2020 - 2025)

Apellis Pharmaceuticals has reported Return on Equity over the past 6 years, most recently at 0.32% for Q4 2025.

  • Quarterly results put Return on Equity at 0.32% for Q4 2025, up 44.0% from a year ago — trailing twelve months through Dec 2025 was 0.32% (up 44.0% YoY), and the annual figure for FY2025 was 0.41%, up 42.0%.
  • Return on Equity for Q4 2025 was 0.32% at Apellis Pharmaceuticals, down from 0.24% in the prior quarter.
  • Over the last five years, Return on Equity for APLS hit a ceiling of 9.36% in Q2 2021 and a floor of 4.46% in Q4 2021.
  • Median Return on Equity over the past 5 years was 0.69% (2022), compared with a mean of 0.28%.
  • Peak annual rise in Return on Equity hit 411bps in 2022, while the deepest fall reached -988bps in 2022.
  • Apellis Pharmaceuticals' Return on Equity stood at 4.46% in 2021, then surged by 92bps to 0.35% in 2022, then crashed by -608bps to 2.48% in 2023, then soared by 70bps to 0.75% in 2024, then soared by 58bps to 0.32% in 2025.
  • The last three reported values for Return on Equity were 0.32% (Q4 2025), 0.24% (Q3 2025), and 1.28% (Q2 2025) per Business Quant data.